Publication:
[Position statement of the Spanish Association of Paediatrics-Spanish Society of Paediatric Infectious Diseases (AEP-SEIP) on the treatment of multidrug-resistant bacterial infections].

dc.contributor.authorAguilera-Alonso, David
dc.contributor.authorEscosa-García, Luis
dc.contributor.authorGoycochea-Valdivia, Walter Alfredo
dc.contributor.authorSoler-Palacín, Pere
dc.contributor.authorSaavedra-Lozano, Jesús
dc.contributor.authorRodrigo, Carlos
dc.contributor.authorCercenado, Emilia
dc.contributor.authorRamos, José Tomás
dc.contributor.authorBaquero-Artigao, Fernando
dc.date.accessioned2023-02-08T14:40:40Z
dc.date.available2023-02-08T14:40:40Z
dc.date.issued2019-10-19
dc.description.abstractA progressive increase in the incidence of infections caused by multidrug-resistant microorganisms is being reported. Among these resistant microorganisms, the main threats are extended-spectrum β-lactamase-, AmpC-, and carbapenemase-producing Gram-negative bacilli, methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. To address this important problem, it is essential to establish pediatric Antimicrobial Stewardship programs, perform active epidemiological surveillance and develop an adequate infection control policy. The therapeutic approach of these infections is often complex, frequently requiring antibiotics with less experience in children. In this position document made by the Spanish Association of Pediatrics and the Spanish Society of Pediatric Infectious Diseases, the epidemiology and treatment of these infections are reviewed according to the best available evidence.
dc.identifier.doi10.1016/j.anpedi.2019.08.002
dc.identifier.essn2341-2879
dc.identifier.pmid31635925
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.anpedi.2019.08.002
dc.identifier.urihttp://hdl.handle.net/10668/15056
dc.issue.number5
dc.journal.titleAnales de pediatria
dc.journal.titleabbreviationAn Pediatr (Engl Ed)
dc.language.isoes
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number351.e1-351.e13
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAmpC β-lactamases
dc.subjectAntimicrobial resistance
dc.subjectBacterias multirresistentes
dc.subjectCarbapenemasas
dc.subjectCarbapenemases
dc.subjectEnterococcus
dc.subjectExtended-spectrum β-lactamases
dc.subjectMethicillin-resistant Staphylococcus aureus
dc.subjectPseudomonas aeruginosa
dc.subjectStaphylococcus aureus resistente a meticilina
dc.subjectβ-lactamasas AmpC
dc.subjectβ-lactamasas de espectro extendido
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshAntimicrobial Stewardship
dc.subject.meshBacterial Infections
dc.subject.meshChild
dc.subject.meshDrug Resistance, Multiple, Bacterial
dc.subject.meshDrug Therapy, Combination
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshPediatrics
dc.subject.meshSpain
dc.title[Position statement of the Spanish Association of Paediatrics-Spanish Society of Paediatric Infectious Diseases (AEP-SEIP) on the treatment of multidrug-resistant bacterial infections].
dc.title.alternativeDocumento de posicionamiento de la Asociación Española de Pediatría-Sociedad Española de Infectología Pediátrica (AEP-SEIP) sobre el tratamiento de las infecciones por bacterias multirresistentes.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number91
dspace.entity.typePublication

Files